Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Interim Efficacy and Safety Analysis of Adjunctive Perampanel in the Adolescent Population from the Extension Phase of 3 Double-Blind, Placebo-Controlled, Phase 3 (Core) Studies in Patients with Refractory Partial-Onset Seizures
Epilepsy/Clinical Neurophysiology (EEG)
(-)
271
Authors/Disclosures
J B. Renfroe, MD (Child Neurology Center of Northwest Florida)
PRESENTER 		Dr. Renfroe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Engage Therapeutics. Dr. Renfroe has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Renfroe has received intellectual property interests from a discovery or technology relating to health care.
Haichen Yang, MD (Amicus Therapeutics) No disclosure on file
Betsy N. Williams, PhD Dr. Williams has received personal compensation for serving as an employee of IQVIA.
No disclosure on file
Scott Kolodny, MD No disclosure on file
Antonio Laurenza, MD (Takeda Pharmacautcals) Dr. Laurenza has received personal compensation for serving as an employee of Takeda. Dr. Laurenza has stock in Takeda.